Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2024-12-03 DOI:10.1111/ctr.70026

James L. Rogers, Jessica Gacki-Smith, Rochell Yacat, Catherine Wicklund, Debra Duquette, John Friedewald, Matthew Cooper, Alexander Gilbert, Akansha Agrawal, Elisa J. Gordon

{"title":"Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study","authors":"James L. Rogers, Jessica Gacki-Smith, Rochell Yacat, Catherine Wicklund, Debra Duquette, John Friedewald, Matthew Cooper, Alexander Gilbert, Akansha Agrawal, Elisa J. Gordon","doi":"10.1111/ctr.70026","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Living kidney donor (LKD) candidates of African ancestry are increasingly asked to undergo <i>Apolipoprotein</i> L1 (<i>APOL1</i>) genetic testing during the donor evaluation process to better understand their risk of kidney disease. LKD candidates’ attitudes about using a clinical chatbot on <i>APOL1</i> remain unknown. This study builds on prior work to culturally adapt the Gia (Genetic Information Assistant) chatbot on <i>APOL1</i> by assessing donor, recipient, and community member attitudes about the Gia chatbot for enhancing the integration of <i>APOL1</i> testing into the LKD clinical evaluation workflow.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study involved focus groups and a post-focus group survey in two US cities about the <i>APOL1</i> Gia chatbot. Qualitative data were analyzed via thematic analysis, and descriptive statistics were used for demographic data.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We conducted 10 focus groups including 54 participants (25 LKDs, 23 community members, and 6 living donor kidney transplant recipients of African ancestry). Five themes emerged: (1) participants supported LKD candidates using the Gia chatbot before the nephrologist clinic visit, (2) participants were interested in undergoing <i>APOL1</i> testing after using Gia, (3) <i>APOL1</i> testing costs may influence LKD candidates’ willingness to get tested, (4) patients of African ancestry may hold varying preferences for using chatbots in the healthcare setting, and (5) individual-level barriers may limit the use of Gia in the healthcare setting.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Individuals of African ancestry were highly receptive to integrating the <i>APOL1</i> chatbot into LKD candidate clinical evaluation, which bodes well for integrating chatbots into the <i>APOL1</i> clinical genetic testing process.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"38 12","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70026","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Living kidney donor (LKD) candidates of African ancestry are increasingly asked to undergo Apolipoprotein L1 (APOL1) genetic testing during the donor evaluation process to better understand their risk of kidney disease. LKD candidates’ attitudes about using a clinical chatbot on APOL1 remain unknown. This study builds on prior work to culturally adapt the Gia (Genetic Information Assistant) chatbot on APOL1 by assessing donor, recipient, and community member attitudes about the Gia chatbot for enhancing the integration of APOL1 testing into the LKD clinical evaluation workflow.

Methods

This study involved focus groups and a post-focus group survey in two US cities about the APOL1 Gia chatbot. Qualitative data were analyzed via thematic analysis, and descriptive statistics were used for demographic data.

Results

We conducted 10 focus groups including 54 participants (25 LKDs, 23 community members, and 6 living donor kidney transplant recipients of African ancestry). Five themes emerged: (1) participants supported LKD candidates using the Gia chatbot before the nephrologist clinic visit, (2) participants were interested in undergoing APOL1 testing after using Gia, (3) APOL1 testing costs may influence LKD candidates’ willingness to get tested, (4) patients of African ancestry may hold varying preferences for using chatbots in the healthcare setting, and (5) individual-level barriers may limit the use of Gia in the healthcare setting.

Conclusions

Individuals of African ancestry were highly receptive to integrating the APOL1 chatbot into LKD candidate clinical evaluation, which bodes well for integrating chatbots into the APOL1 clinical genetic testing process.

查看原文本刊更多论文

对在活体肾供者评估中使用APOL1基因检测聊天机器人的态度：焦点小组研究

背景：越来越多的非洲血统的活体肾供者（LKD）候选人被要求在供者评估过程中进行载脂蛋白L1 （APOL1）基因检测，以更好地了解他们患肾脏疾病的风险。LKD候选人对APOL1使用临床聊天机器人的态度尚不清楚。本研究建立在先前工作的基础上，通过评估供体、受体和社区成员对Gia聊天机器人的态度，在APOL1上对Gia聊天机器人进行文化调整，以加强APOL1测试与LKD临床评估工作流程的整合。方法在美国两个城市对APOL1 Gia聊天机器人进行焦点小组和后焦点小组调查。定性数据采用专题分析，人口统计数据采用描述性统计。结果我们进行了10个焦点小组，包括54名参与者（25名lkd， 23名社区成员和6名非洲血统的活体肾移植受者）。出现了五个主题：(1)受试者支持LKD患者在肾病专家门诊就诊前使用Gia聊天机器人；(2)受试者在使用Gia聊天机器人后有兴趣进行APOL1测试；(3)APOL1测试成本可能影响LKD患者接受测试的意愿；(4)非洲血统患者在医疗保健环境中使用聊天机器人的偏好可能不同。(5)个人层面的障碍可能会限制Gia在医疗保健环境中的使用。结论非洲人对将APOL1聊天机器人整合到LKD候选人的临床评估中具有较高的接受度，这预示着将聊天机器人整合到APOL1临床基因检测过程中是一个良好的兆头。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.